Randomized trial shows 43% reduction in cardiovascular events among dialysis patients using fish oil — Evidence Review
Published in The New England Journal of Medicine, by researchers from Monash Health, School of Clinical Sciences at Monash University, University Health Network, University of Calgary
Researched by
— the AI search engine for science
Table of Contents
A large international randomized trial found that daily fish oil supplementation reduced major cardiovascular events by 43% in people undergoing dialysis for kidney failure. Most prior research in this area has been inconclusive, but this new finding from the New England Journal of Medicine aligns with some earlier studies suggesting potential cardiovascular benefits of omega-3 fatty acids in high-risk populations.
- Several smaller trials and meta-analyses have previously suggested that omega-3 supplementation may reduce certain cardiovascular risks in dialysis patients, but evidence has been inconsistent and often limited by small sample sizes or short follow-up periods 1 2 3 10.
- Some large-scale systematic reviews and meta-analyses in broader populations have found little or no effect of omega-3 supplementation on cardiovascular outcomes, highlighting that benefits may be more pronounced in select high-risk groups, such as those on dialysis 8 9 10.
- Earlier studies in dialysis patients have reported improvements in surrogate markers (such as inflammation or lipid profiles) with fish oil supplementation, but clear evidence for major clinical event reduction has been lacking until now 1 4 5.
Study Overview and Key Findings
Patients with kidney failure who require dialysis face a markedly elevated risk of cardiovascular disease, including heart attack and stroke, and there are few proven strategies to meaningfully reduce this risk. The PISCES trial was conducted to address the longstanding uncertainty about whether omega-3 fatty acids—commonly found in fish oil—could provide real-world cardiovascular protection for this vulnerable population. The results, presented at a major nephrology conference and published in a leading medical journal, mark a significant development in a field where most prior cardiovascular interventions have failed to show benefit.
| Property | Value |
|---|---|
| Study Year | 2025 |
| Organization | Monash Health, School of Clinical Sciences at Monash University, University Health Network, University of Calgary |
| Journal Name | The New England Journal of Medicine |
| Authors | Kevan Polkinghorne, Charmaine Lok |
| Population | Patients undergoing dialysis for kidney failure |
| Sample Size | n=1,228 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Major cardiovascular events including heart attack and stroke |
| Results | 43% lower rate of serious cardiovascular events in fish oil group |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus database, which covers over 200 million research publications. The following search queries were used to identify relevant literature:
- omega-3 fish oil dialysis patients
- cardiovascular events fish oil supplements
- heart attack stroke prevention dialysis
Literature Review Table
| Topic | Key Findings |
|---|---|
| Does fish oil or omega-3 supplementation prevent cardiovascular events in dialysis patients? | - Some RCTs and meta-analyses suggest omega-3 supplementation may reduce cardiovascular mortality in hemodialysis patients, but evidence has been limited and not always consistent 1 2 3. - Prior studies often showed improvements in surrogate markers rather than definitive reductions in major clinical events 1 3 5. |
| How effective is omega-3 supplementation for cardiovascular prevention in high-risk and general populations? | - Meta-analyses indicate that omega-3 supplementation may have modest benefits in high-risk populations, but effects in the general population are small or absent, with most benefits observed in secondary prevention settings 6 7 9 10. - Several large systematic reviews found little or no effect on overall mortality or cardiovascular events 8 10. |
| What mechanisms might underlie cardiovascular benefits of fish oil in dialysis patients? | - Some trials found that omega-3 supplementation in dialysis patients improves biomarkers such as blood omega-3 levels, C-reactive protein, and vitamin D activation, potentially contributing to cardioprotection 1 4 5. - Anti-inflammatory and lipid-modifying effects are observed, though the clinical impact of these changes remains uncertain 1 4 5. |
| What are the risks and limitations of omega-3 supplementation in this population? | - Adverse effects are generally minor, with gastrointestinal complaints most commonly reported 3. - Evidence for long-term safety and efficacy is still limited, and previous studies have been hindered by small sample sizes, short follow-up, and lack of hard clinical endpoints 3 8. |
Does fish oil or omega-3 supplementation prevent cardiovascular events in dialysis patients?
The new PISCES trial provides robust evidence for a reduction in major cardiovascular events with fish oil supplementation in hemodialysis patients, a finding that builds upon but substantially exceeds the strength of earlier evidence. Previous studies in this population have mostly been small or focused on surrogate endpoints, leaving questions about real-world cardiovascular benefits unresolved.
- Prior RCTs and meta-analyses suggested possible reductions in cardiovascular mortality with omega-3 supplementation in hemodialysis patients, but findings were often inconclusive or low-quality due to small sample sizes 1 2 3.
- Improvements in biomarkers such as omega-3 index and C-reactive protein were observed in earlier trials, but without confirming reductions in major clinical events 1.
- The PISCES trial is notable for its large sample size and focus on hard clinical endpoints, addressing limitations of previous research 2 3.
- Earlier reviews called for large-scale RCTs with long-term follow-up and clinical outcomes, which the new study provides 3.
How effective is omega-3 supplementation for cardiovascular prevention in high-risk and general populations?
While some benefits of omega-3 supplementation have been demonstrated in high-risk groups, most large-scale studies in the general population have found minimal or no effect on cardiovascular outcomes. The pronounced effect seen in the dialysis population in the new study may reflect their unique risk profile and lower baseline omega-3 levels.
- Meta-analyses and systematic reviews show that omega-3 supplementation has greater benefit in secondary prevention or high-risk populations compared to the general public 6 7 9 10.
- Several large reviews found little or no effect on all-cause mortality or cardiovascular events in broader populations, suggesting that the benefit may be specific to groups like dialysis patients 8 10.
- The magnitude of effect in the new dialysis study is larger than typically seen in studies of the general population, highlighting a possible risk-group specific benefit 9 10.
- Dose-response relationships have been observed, with higher doses of marine omega-3 associated with greater risk reductions in some analyses 10.
What mechanisms might underlie cardiovascular benefits of fish oil in dialysis patients?
The biological mechanisms by which omega-3 fatty acids may reduce cardiovascular risk in dialysis patients include anti-inflammatory effects, improvement in lipid profiles, and modulation of vitamin D metabolism. However, the extent to which these changes translate into fewer major events has been unclear until now.
- Omega-3 supplementation in dialysis patients raises blood levels of EPA and DHA and improves the omega-3 index, a marker of cardioprotection 1.
- Reductions in inflammatory markers (e.g., C-reactive protein) and changes in vitamin D activation and fetuin-A levels have been observed, suggesting potential pathways for cardiovascular benefit 1 4.
- Improvements in lipid profiles, including reduced triglycerides, have been reported, though the impact on clinical outcomes was not previously established 1 5.
- The PISCES trial provides outcome-based evidence that may validate these mechanisms in a clinical context 1 4 5.
What are the risks and limitations of omega-3 supplementation in this population?
Despite generally favorable safety profiles, previous studies have noted limitations such as small sample sizes, short durations, and lack of compliance data. The long-term safety and optimal dosing of omega-3 supplementation in dialysis patients remain to be fully clarified.
- Adverse effects are mostly minor, with gastrointestinal side effects most commonly reported 3.
- Previous research has been limited by small study sizes, supraphysiologic dosing, and brief follow-up, making it difficult to assess long-term risks or benefits 3 8.
- The recent large-scale trial addresses some of these limitations but further long-term data are needed to confirm durability and safety 3 8.
- No significant increase in serious adverse events such as bleeding has been consistently observed, but ongoing surveillance is warranted 2 3.
Future Research Questions
Large-scale evidence from the PISCES trial marks an important advance, but further research is needed to clarify the broader applicability, long-term safety, and optimal implementation of omega-3 supplementation in dialysis patients. Key areas for future investigation include whether similar benefits are seen in other high-risk populations, the effects of different dosing regimens, and the impact on quality of life and non-cardiovascular outcomes.
| Research Question | Relevance |
|---|---|
| Do omega-3 supplements reduce cardiovascular risk in peritoneal dialysis patients? | The current study focused on hemodialysis patients; peritoneal dialysis patients may have different risk profiles and responses 13. Exploring efficacy in this group could inform tailored interventions. |
| What are the long-term safety and efficacy outcomes of high-dose fish oil in dialysis patients? | Most studies, including the new trial, have relatively short follow-up. Long-term data are needed to assess sustained benefit and monitor for rare adverse effects 3 8. |
| Does omega-3 supplementation improve quality of life or non-cardiovascular outcomes in dialysis patients? | While cardiovascular outcomes are critical, impacts on quality of life, inflammation, nutrition, and other complications in dialysis patients also warrant investigation 5. |
| Is there a dose-response relationship between omega-3 intake and cardiovascular event reduction in dialysis patients? | Some meta-analyses suggest risk reductions may be dose-related, but the optimal dose for efficacy and safety in dialysis remains uncertain 10. |
| Are the cardiovascular benefits of omega-3 supplements generalizable to other high-risk populations? | The strong effect observed in dialysis patients raises questions about applicability to other groups with elevated cardiovascular risk, such as those with advanced heart failure or diabetes 7 9. |